Skip to main content
evidena care

Interactions

Cannabis and antidepressants: interactions and risks

Many people in cannabis therapy also take an antidepressant. Which combinations are well studied and where caution is needed.

Key points

  • CBD inhibits several liver enzymes. With citalopram and escitalopram, blood levels rose in a small study when CBD was added.
  • For sertraline, fluoxetine and mirtazapine, CBD showed only minor effects on breakdown in the laboratory. For venlafaxine, duloxetine and bupropion, clinical data are largely lacking.
  • THC can intensify tiredness and dizziness on mirtazapine or tricyclics. With tricyclics, cases of racing heart and confusion have been described.
  • THC is associated with a higher risk of psychosis and can affect mood. This belongs in the psychiatric assessment.
  • Never stop antidepressants abruptly: discontinuation symptoms are common. Changes only in agreement with your doctor.

Cannabis and antidepressants cannot be classified across the board as “compatible” or “dangerous”. What matters is which antidepressant you take and whether THC, CBD or both are involved. CBD inhibits liver enzymes via which several antidepressants are broken down. For citalopram and escitalopram, a rise in blood levels has been measured in a small study; for many other active substances there are only theoretical indications.1,4

THC acts directly on the mind and circulation. Together with sedating antidepressants such as mirtazapine or amitriptyline, tiredness and dizziness can add up. With depression, there is also the question of how THC affects mood. This assessment belongs with your doctor, ideally together with your psychiatrist.2,6

How cannabis and antidepressants can affect each other

There are two routes. In a pharmacokinetic interaction, one active substance changes the breakdown of another, usually via enzymes of the cytochrome P450 family (CYP) in the liver. Many antidepressants are broken down via CYP2C19, CYP2D6 or CYP3A4. In a pharmacodynamic interaction, effects add up directly, for example tiredness, dizziness or a fast pulse.2,4

For breakdown, CBD is the main factor. In a controlled study with healthy adults, a high single oral dose of 640 mg CBD together with 20 mg THC inhibited mainly CYP2C19, and also CYP2C9, CYP3A4 and CYP1A2. The comparison dose with THC alone showed no corresponding inhibition. The results cannot simply be transferred to lower doses.3

A systematic review of interactions of THC, CBD and cannabis concludes that clinical data in humans are lacking for most combinations. Many warnings are based on laboratory experiments or model calculations. A shared breakdown pathway is a reason to look more closely, but not yet proof of a clinically relevant interaction.4

Cannabis and SSRIs: sertraline, escitalopram, fluoxetine

SSRIs (selective serotonin reuptake inhibitors) are among the most frequently prescribed antidepressants. The best-studied combination is CBD with citalopram and its variant escitalopram. In the laboratory, CBD inhibited the breakdown of both active substances via CYP3A4 and CYP2C19 at concentrations that are also reached in the body. In six people with an anxiety disorder who were stable on citalopram or escitalopram and in a study additionally received increasing CBD doses of 200 to 800 mg per day, citalopram levels rose considerably. Whether this led to more side effects remained unclear.1

For sertraline and fluoxetine, the same paper found only a minor influence of CBD on breakdown in the laboratory. There are hardly any data in humans on this. A review with model calculations for adolescents estimated that CBD and THC can increase the levels of sertraline and escitalopram. In an analysis of the US adverse event reporting system, dizziness, tiredness, diarrhoea and cough were reported more often when CBD was combined with SSRIs broken down via CYP2C19. Such reporting data show signals, but not a cause.1,2

The same review points out that cannabinoids also affect serotonin signalling. What this means clinically for the combination with SSRIs has not been clarified. An important point is that starting, increasing or leaving out cannabis can also change the levels of an SSRI.2

SNRIs, mirtazapine and bupropion: few data

For the SNRIs venlafaxine and duloxetine and for bupropion, there are hardly any clinical studies on the combination with cannabis. These active substances are also broken down via CYP enzymes in the liver. That CBD can affect these pathways is derived from laboratory experiments; a clinically measurable interaction has not been demonstrated for these active substances.4

The breakdown of mirtazapine was hardly affected by CBD in the laboratory. With mirtazapine, the effect is more in the foreground: it often causes tiredness. THC can additionally intensify tiredness, drowsiness and impaired ability to react. This should be borne in mind particularly in the evening, when driving and in older people at risk of falls. The same applies if sleeping pills, benzodiazepines or alcohol are also involved, because the depressant effects of several substances can add up.1,4

Cannabis and tricyclics such as amitriptyline: heart and circulation

Tricyclic antidepressants such as amitriptyline are also used for pain and sleep disorders, often at a low dose. They can cause tiredness, increase the pulse and lower blood pressure on standing up. THC has similar circulatory effects, which can add up.4

In an older case report, doctors described four adolescents who were receiving a tricyclic for ADHD and developed temporary confusion, delirium and racing heart after smoking cannabis. Four cases allow no statement about frequency. They are, however, a reason for the combination to be medically supervised, especially in people with heart disease.5

MAO inhibitors such as moclobemide are used less often today. There are practically no clinical data on the combination with cannabis. Anyone taking an MAO inhibitor should have every additional substance checked by a doctor beforehand.4

THC, mood and risk of psychosis

With antidepressants, it is not only about laboratory values, but also about the underlying condition. In a European case-control study with 901 people with first-episode psychosis and 1,237 controls, daily cannabis use was associated with a roughly threefold increased risk of a psychotic disorder, and daily use of high-THC cannabis with an almost fivefold risk.6

A meta-analysis found that cannabis use in adolescence was associated with a higher risk of depression and suicidal thoughts in young adulthood. The authors described the individual risk as moderate to low. Such observational studies do not prove a cause, but they are important for the assessment in existing depression.7

You can read more about when a pre-existing mental illness speaks against cannabis therapy in the article Cannabis medicine despite a pre-existing mental illness?.

Never stop antidepressants abruptly

Some people hope to get rid of their antidepressant with cannabis therapy. Never stop an antidepressant on your own, not even gradually without supervision. A meta-analysis with over 21,000 people found that around a third had at least one discontinuation symptom after stopping an antidepressant. Taking the placebo groups into account, the researchers estimated the proportion at around 15 per cent. Discontinuation symptoms were more frequent with venlafaxine, desvenlafaxine, imipramine and escitalopram.8

Discontinuation symptoms can include dizziness, sleep disturbances, irritability or flu-like symptoms. In addition, the depression can return. Whether and how an antidepressant is changed is decided only by your doctor.8

What you should discuss with your doctor or psychiatrist

  • which antidepressant you take, at what dose and since when
  • whether you use CBD products, over-the-counter preparations or non-prescribed cannabis
  • previous episodes of psychosis, mania or suicidal thoughts, including in the family
  • other medicines that cause tiredness, such as sleeping pills or painkillers
  • heart disease, heart rhythm disorders or dizziness on standing up

After starting cannabis therapy, new tiredness, inner restlessness, palpitations or a change in mood are important feedback. With CBD and citalopram or escitalopram, the authors of the study recommend particular attention to new side effects.1 An overview of other combinations can be found in the article Cannabis and medicines: which interactions matter? and on the overview page Interactions.

How it works at evidena

At evidena, a doctor reviews your entire medication in a consultation, including antidepressants, and your psychiatric history. Whether cannabis therapy is an option is decided individually by the doctor. A prescription is valid for a treatment period of 3 months and must be filled at a pharmacy within 1 month. You can book appointments at portal.evidena.care. We answer questions via WhatsApp or at info@evidena.care. How it works explains the process.

Conclusion

Cannabis and antidepressants are not fundamentally incompatible. The best-documented finding is that CBD can increase the levels of citalopram and escitalopram; for most other active substances the data are thin. With mirtazapine and tricyclics, tiredness and circulatory effects can add up, and THC can affect the psychiatric situation. Never change your antidepressant on your own, only in agreement with your doctor.

This article is for general information and does not replace individual medical advice.

Frequently asked questions

May I take cannabis if I take an antidepressant?

The combination is not ruled out in principle. Whether it is an option depends on the active substance, your psychiatric history and other medicines, and is assessed by a doctor.

Does CBD increase the level of escitalopram?

In a small study with six people, citalopram levels rose considerably with additional CBD. Whether this causes more side effects remained unclear.

Is cannabis problematic with mirtazapine or amitriptyline?

Both medicines often cause tiredness, and THC can intensify this. With tricyclics such as amitriptyline, cases of racing heart and confusion after cannabis use have also been described.

Can I stop my antidepressant if I am prescribed cannabis?

No, not on your own. Stopping abruptly without medical supervision can trigger discontinuation symptoms and a relapse. Any change belongs in the hands of your doctor.

Can cannabis make depression worse?

Studies show associations between cannabis use in adolescence and later depression, and between daily use of high-THC cannabis and psychosis. You should discuss changes in mood with your doctor promptly.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Anderson LL et al. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021;41(5):525–533. doi:10.1097/JCP.0000000000001427
  2. Vaughn SE et al. The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. J Pers Med. 2021;11(7):615. doi:10.3390/jpm11070615
  3. Bansal S et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther. 2023;114(3):693–703. doi:10.1002/cpt.2973
  4. Nachnani R et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. doi:10.3389/fphar.2024.1282831
  5. Wilens TE et al. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry. 1997;36(1):45–48. doi:10.1097/00004583-199701000-00016
  6. Di Forti M et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–436. doi:10.1016/S2215-0366(19)30048-3
  7. Gobbi G et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(4):426–434. doi:10.1001/jamapsychiatry.2018.4500
  8. Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526–535. doi:10.1016/S2215-0366(24)00133-0

Written by evidena.care editorial team · Published 11 November 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.